<DOC>
	<DOCNO>NCT00864890</DOCNO>
	<brief_summary>The purpose study evaluate compare relative bioavailability , therefore bioequivalence two formulation Citalopram single dose administration feed condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Citalopram 40 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : Single Dose Crossover Comparative Bioavailability Study Citalopram 40 mg Tablets Healthy Male Volunteers/Fed State Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Availability subject entire study period willingness adhere protocol requirement evidence informed consent form duly sign subject . 2 . Males age 18 50 year body mass index ( BMI ) within 1930 ; demographic data ( sex , age , ethnic group , body weight , height smoke habit ) record report final report . 3 . Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance must record CRF . 4 . Healthy accord laboratory result physical examination 5 . Normal cardiovascular function accord ECG . 6 . Subjects non exsmokers . 1 . Significant history hypersensitivity citalopram relate product well severe hypersensitivity reaction ( like angioedema ) drug . 2 . Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . 3 . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . 4 . Use MAO inhibitor within 14 day day 1 study 5 . Maintenance therapy drug , significant history drug dependency , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) , serious Psychological disease . 6 . Any clinically significant illness previous 28 day day 1 study . 7 . Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc. ) . 8 . Participation another clinical trial previous 28 day day 1 study . 9 . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . 10 . Positive urine screen drug abuse . 11 . Positive result HIV , HBsAg antiHCV test 12 . History faint upon blood sampling</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Citalopram</keyword>
	<keyword>Healthy subject</keyword>
</DOC>